Literature DB >> 22323824

Activation of adenosine₁ receptors induces antidepressant-like, anti-impulsive effects on differential reinforcement of low-rate 72-s behavior in rats.

Gerard J Marek1.   

Abstract

Stress and psychiatric illness have been associated with a dysregulation of glutamatergic neurotransmission. Recently, positive allosteric modulators (PAMs) of the metabotropic glutamate 2 (mGlu₂) receptor have been found to exert antidepressant-like activity in rats performing under a differential reinforcement of low rate (DRL) 72-s schedule. An autoreceptor role at glutamatergic synapses is the most salient physiological role played by the mGlu₂ receptor. Adenosine A₁ receptors play a heteroreceptor role at many of the same forebrain synapses where mGlu₂ autoreceptors are found. Agonists and/or PAMs of mGlu₂ receptors act similarly to adenosine A₁ receptor agonists with respect to a wide range of electrophysiological, biochemical, and behavioral responses mediated by limbic circuitry thought to play a role in the pathophysiology of neuropsychiatric disease and to mediate therapeutic drug effects. Therefore, the role of adenosine A₁ receptor activation on rat DRL 72-s behavior was explored to provide preclinical evidence consistent or inconsistent with potential antidepressant effects. The adenosine A₁ receptor agonist N⁶-cyclohexyladenosine (CHA) increased the reinforcement rate, decreased the response rate, and induced a rightward shift in inter-response time distributions in a dose-dependent fashion similar to most known antidepressant drugs. The adenosine A₁ receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) blocked these antidepressant-like effects. These novel observations with CHA and DPCPX suggest that activation of adenosine A₁ receptors could contribute to antidepressant effects, in addition to previous preclinical reports of anxiolytic and antipsychotic effects. By implication, targeting a dysregulated glutamatergic system may be an important principle in discovering novel antidepressant agents that may also possess anti-impulsive activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22323824      PMCID: PMC3336810          DOI: 10.1124/jpet.112.191718

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  47 in total

1.  Operant learning and differential-reinforcement-of-low-rate 36-s responding in 5-HT1A and 5-HT1B receptor knockout mice.

Authors:  Tommy Pattij; Laus M Broersen; Judith van der Linde; Lucianne Groenink; Jan van der Gugten; Robert A A Maes; Berend Olivier
Journal:  Behav Brain Res       Date:  2003-05-15       Impact factor: 3.332

2.  Localization of adenosine A1-receptors to the terminals of the perforant path.

Authors:  M Dragunow; K Murphy; R A Leslie; H A Robertson
Journal:  Brain Res       Date:  1988-10-18       Impact factor: 3.252

3.  Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists.

Authors:  R F Bruns
Journal:  Can J Physiol Pharmacol       Date:  1980-06       Impact factor: 2.273

Review 4.  Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system.

Authors:  D D Schoepp
Journal:  J Pharmacol Exp Ther       Date:  2001-10       Impact factor: 4.030

5.  A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex.

Authors:  G J Marek; R A Wright; J C Gewirtz; D D Schoepp
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

6.  Presynaptic inhibition of synaptic transmission by adenosine in rat subthalamic nucleus in vitro.

Authors:  K-Z Shen; S W Johnson
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

Review 7.  Adenosine receptors in the nervous system: pathophysiological implications.

Authors:  J A Ribeiro; A M Sebastião; A de Mendonça
Journal:  Prog Neurobiol       Date:  2002-12       Impact factor: 11.685

8.  Glutamate receptor activation is involved in 5-HT2 agonist-induced Arc gene expression in the rat cortex.

Authors:  Q Pei; R Tordera; M Sprakes; T Sharp
Journal:  Neuropharmacology       Date:  2004-03       Impact factor: 5.250

9.  Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A1 and A2A receptors.

Authors:  Manuella P Kaster; Angelo Oscar Rosa; Matheus M Rosso; Eduardo C Goulart; Adair R S Santos; Ana Lúcia S Rodrigues
Journal:  Neurosci Lett       Date:  2004-01-23       Impact factor: 3.046

10.  Evaluation of 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET.

Authors:  Andreas Bauer; Marcus H Holschbach; Markus Cremer; Simone Weber; Christian Boy; N Jon Shah; Ray A Olsson; Horst Halling; Heinz H Coenen; Karl Zilles
Journal:  J Nucl Med       Date:  2003-10       Impact factor: 10.057

View more
  9 in total

1.  Neurobehavioral and genotoxic evaluation of (-)-linalool in mice.

Authors:  Vanessa Coelho; Leidiane Mazzardo-Martins; Daniel Fernandes Martins; Adair Roberto Soares Santos; Lucimar Filot da Silva Brum; Jaqueline Nascimento Picada; Patrícia Pereira
Journal:  J Nat Med       Date:  2013-02-24       Impact factor: 2.343

2.  Creatine, similarly to ketamine, affords antidepressant-like effects in the tail suspension test via adenosine A₁ and A2A receptor activation.

Authors:  Mauricio P Cunha; Francis L Pazini; Julia M Rosa; Ana B Ramos-Hryb; Ágatha Oliveira; Manuella P Kaster; Ana Lúcia S Rodrigues
Journal:  Purinergic Signal       Date:  2015-02-22       Impact factor: 3.765

3.  Extending the Specificity of DRL 72-s Behavior for Screening Antidepressant-Like Effects of Glutamatergic Clinically Validated Anxiolytic or Antidepressant Drugs in Rats.

Authors:  Gerard J Marek; Allyson A Salek
Journal:  J Pharmacol Exp Ther       Date:  2020-04-07       Impact factor: 4.030

4.  Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity.

Authors:  Dilip K Tosh; Silvia Paoletta; Francesca Deflorian; Khai Phan; Steven M Moss; Zhan-Guo Gao; Xiaohui Jiang; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2012-09-10       Impact factor: 7.446

5.  Oral administration of inosine produces antidepressant-like effects in mice.

Authors:  Junko Muto; Hosung Lee; Hyunjin Lee; Akemi Uwaya; Jonghyuk Park; Sanae Nakajima; Kazufumi Nagata; Makoto Ohno; Ikuroh Ohsawa; Toshio Mikami
Journal:  Sci Rep       Date:  2014-02-26       Impact factor: 4.379

Review 6.  The Purinergic System as a Target for the Development of Treatments for Bipolar Disorder.

Authors:  Maria Carolina Bittencourt Gonçalves; Roberta Andrejew; Carolina Gubert
Journal:  CNS Drugs       Date:  2022-07-13       Impact factor: 6.497

7.  Genomic-Analysis-Oriented Drug Repurposing in the Search for Novel Antidepressants.

Authors:  Mohammad Hendra Setia Lesmana; Nguyen Quoc Khanh Le; Wei-Che Chiu; Kuo-Hsuan Chung; Chih-Yang Wang; Lalu Muhammad Irham; Min-Huey Chung
Journal:  Biomedicines       Date:  2022-08-11

Review 8.  Convergent pharmacological mechanisms in impulsivity and addiction: insights from rodent models.

Authors:  B Jupp; J W Dalley
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

9.  β2-Adrenergic Receptor Activation Suppresses the Rat Phenethylamine Hallucinogen-Induced Head Twitch Response: Hallucinogen-Induced Excitatory Post-synaptic Potentials as a Potential Substrate.

Authors:  Gerard J Marek; Brian P Ramos
Journal:  Front Pharmacol       Date:  2018-02-08       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.